Skip to main content

Table 1 Summary of trials mentioned in current review

From: Optimizing peripheral blood stem cells transplantation outcome through amend relapse and graft failure: a review of current literature

Type of DLI Authors Case number Mean age of patients (years) Pre-DLI treatment(s) Diagnosis DLI modality T cell dosage Series of DLI (mean) GVHD Response rate (CR)
Therapeutic DLI
 Lymphodepletion (LDP) Warlick et al. [7] 35 51 LPD ALL, AML, MDS, NHL, CLL, MM Unstimulated leukapheresis 0.5 × 108/kg
1 × 108/kg
1 II–IV (25%)
II–IV (66%)
CR 45%
CR 53%
Guillaume et al. [36] 18 45 Escalation LDP ALL, AML, MDS, NHL, HD, MM Not mentioned 1–5 × 107/kg 1–3 II–IV (29.4%) CR 38.9%
 With pharmacotherapy Schroeder et al. [16] 154 55 5-Azacytidine AML, MDS Not mentioned 31.2 × 106/kg (mean) 1–3 Acute (23%) CR 27%
Schroeder et al. [17] 30 55 Azacitidine AML, MDS Dose-escalating donor lymphocyte 1.5 × 106/kg–1.5 × 108/kg 1–4 II–IV (30%) CR 38.1%
 G-CSF-primed Yan et al. [48] 50 22 Chemotherapy ALL, AML G-CSF primed 0.9–4.2 × 108/kg 1 II–IV (62.7%) CR 32%
 Prophylactic Wang et al. [47] 123 40 No treatment ALL, AML Prophylactic (G-CSF primed type) 1.8 × 108/kg Not mentioned II–IV (17%) Not mentioned
Kumar et al. [39] 18 60 Immunosuppressive therapy ALL, AML, MDS Prophylactic ex vivo costimulated T cells 1–10 × 107/kg 1–2 Acute (27.8%) CR 4 of 18
  1. AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML chronic myeloid leukemia, CLL chronic lymphoblastic leukemia, DLI donor lymphocyte infusion, G-CSF granulocyte-colony stimulating factor, HD Hodgkin disease, MDS myelodysplastic syndrome, MM multiple myeloma, MPN myeloproliferative syndrome, NHL non-Hodgkin lymphoma